Natera, Inc. (NASDAQ:NTRA – Get Free Report) insider Solomon Moshkevich sold 1,204 shares of the business’s stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $254.07, for a total transaction of $305,900.28. Following the transaction, the insider owned 132,429 shares of the company’s stock, valued at $33,646,236.03. This represents a 0.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Solomon Moshkevich also recently made the following trade(s):
- On Monday, July 27th, Solomon Moshkevich sold 1,010 shares of Natera stock. The stock was sold at an average price of $260.49, for a total value of $263,094.90.
- On Wednesday, July 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $272.90, for a total value of $818,700.00.
- On Monday, June 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $218.43, for a total value of $655,290.00.
- On Tuesday, May 26th, Solomon Moshkevich sold 1,652 shares of Natera stock. The stock was sold at an average price of $202.84, for a total value of $335,091.68.
- On Friday, May 1st, Solomon Moshkevich sold 3,405 shares of Natera stock. The stock was sold at an average price of $203.69, for a total value of $693,564.45.
Natera Trading Up 0.6%
Shares of NTRA stock opened at $253.82 on Thursday. The stock has a 50 day moving average of $244.16 and a 200 day moving average of $221.65. The stock has a market cap of $36.35 billion, a P/E ratio of -155.72 and a beta of 1.51. Natera, Inc. has a twelve month low of $131.81 and a twelve month high of $288.04.
Key Headlines Impacting Natera
- Neutral Sentiment: Most notably, CFO Michael Burkes Brophy sold 5,064 shares for approximately $1.28 million, while CEO Steven Leonard Chapman sold 5,770 shares for about $1.48 million. Both executives cited pre-arranged Rule 10b5-1 trading plans and said the sales were made to cover tax-withholding obligations related to vested equity awards, reducing the likelihood that the transactions signal a loss of confidence. CFO SEC filing CEO SEC filing
- Neutral Sentiment: Insiders John Fesko and Solomon Moshkevich also sold a combined 3,927 shares worth approximately $1.01 million under similar pre-arranged plans to meet tax obligations. They retained substantial holdings after the sales, further limiting the negative interpretation. Fesko SEC filing Moshkevich SEC filing
- Negative Sentiment: The concentration of sales by the CEO, CFO and other insiders may nevertheless create modest short-term selling pressure or raise valuation concerns, particularly because NTRA remains well below its 52-week high and carries a negative trailing price-to-earnings ratio. However, the filings contain no new operational or financial warning.
Analyst Ratings Changes
Several research firms have recently weighed in on NTRA. Canaccord Genuity Group lifted their target price on shares of Natera from $285.00 to $330.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Natera in a report on Friday, July 17th. UBS Group set a $260.00 price target on shares of Natera in a research report on Wednesday, June 24th. The Goldman Sachs Group started coverage on shares of Natera in a report on Friday, June 5th. They issued a “neutral” rating and a $245.00 price objective for the company. Finally, Morgan Stanley upped their price objective on shares of Natera from $250.00 to $310.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Natera presently has a consensus rating of “Moderate Buy” and a consensus target price of $267.83.
Read Our Latest Report on NTRA
Institutional Trading of Natera
A number of institutional investors and hedge funds have recently made changes to their positions in NTRA. Reflection Asset Management purchased a new position in shares of Natera during the 4th quarter valued at approximately $29,000. Elevation Wealth Partners LLC purchased a new stake in Natera in the 2nd quarter worth $30,000. Palladiem LLC purchased a new stake in Natera in the 4th quarter worth $31,000. Horizon Investments LLC acquired a new position in Natera during the third quarter worth $32,000. Finally, International Assets Investment Management LLC raised its position in Natera by 132.9% during the first quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock worth $35,000 after acquiring an additional 97 shares during the period. 99.90% of the stock is currently owned by hedge funds and other institutional investors.
About Natera
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
Featured Stories
- Five stocks we like better than Natera
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
